Posted by Michael Wonder on 03 Mar 2022
U.S. Food and Drug Administration grants Cabaletta Bio fast track designation for MuSK-CAART
1 March 2022 - Fast Track Designation granted to improve activities of daily living and muscle strength in patients with MuSK antibody-positive myasthenia gravis.
Cabaletta Bio today announced that the U.S. FDA has granted fast track designation for MuSK-CAART, or muscle specific kinase (MuSK) chimeric autoantibody receptor T (MuSK-CAART) cells, to improve activities of daily living and muscle strength in patients with MuSK antibody positive myasthenia gravis.
